Steep Hill Inc (GPIN) AI Stock Analysis

Top Page

Steep Hill Inc

(CNQX:GPIN)

Select Model

Rating:49Neutral

Price Target:CAD 0.06▼(-69.44% Downside)

Action:reiterated

Date:12/30/25

The score is held back primarily by weak and unstable operating results and recent cash burn despite a low-debt balance sheet. Technical signals are neutral-to-soft, while valuation looks optically cheap on P/E but is discounted by earnings quality concerns. The reverse takeover and related restructuring/financing are meaningful potential catalysts but introduce significant execution and transition risk.

Positive Factors

Industry PartnershipsPartnerships with industry players and regulatory bodies enhance Steep Hill's credibility and revenue potential, supporting long-term business sustainability and compliance.

Negative Factors

Operational InefficienciesPersistent operational inefficiencies, as indicated by negative margins, suggest challenges in cost management and profitability, affecting long-term business viability.

Steep Hill Inc (GPIN) vs. iShares MSCI Canada ETF (EWC)

Market Cap: CAD 889.83K
Dividend Yield: ―
Average Volume (3M): 12.56K
Price to Earnings (P/E): 0.4
Beta (1Y): 0.56
Revenue Growth: ―
EPS Growth: -150.05%
Country: Canada
Employees: 6
Sector: Financial
Sector Strength: 68
Industry: Drug Manufacturers - Specialty & Generic

Steep Hill Inc Business Overview & Revenue Model

Company Description

Steep Hill Inc., a cannabis science and technology company, provides laboratory testing, quality assurance, and data analytics services in Canada and the United States. It offers analytical testing services, such as cannabinoids, terpenes, pesticides...

How the Company Makes Money

null

Steep Hill Inc Financial Statement Overview

Summary

Balance sheet strength (low/no debt and positive equity) is a key support, but it is outweighed by weak operating fundamentals: persistent negative EBIT/EBITDA, unreliable/volatile revenue and gross profit, and recent negative operating/free cash flow indicating ongoing cash burn.

Income Statement

24Negative

Balance Sheet

68Positive

Cash Flow

31Negative

Steep Hill Inc Technical Analysis

Technical Analysis SentimentNegative

Last Price0.18

Price Trends

50DMA0.23Negative

100DMA0.28Negative

200DMA0.32Negative

Market Momentum

MACD-0.02Negative

RSI34.07Neutral

STOCH46.67Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:GPIN, the sentiment is Negative. The current price of 0.18 is below the 20-day moving average (MA) of 0.20, below the 50-day MA of 0.23, and below the 200-day MA of 0.32, indicating a bearish trend. The MACD of -0.02 indicates Negative momentum. The RSI at 34.07 is Neutral, neither overbought nor oversold. The STOCH value of 46.67 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:GPIN.

Steep Hill Inc Peers Comparison

Overall Rating

UnderperformOutperform

Sector (68)

Financial Indicators

TSE:GPIN against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	68Neutral	$18.00B	11.42	9.92%	3.81%	9.73%	1.22%
TSE:INNO	56Neutral	CAD 8.55M	-6.55	-19.37%	―	-19.20%	42.54%
TSE:LABS	49Neutral	CAD 27.77M	-5.60	-13.79%	―	-6.74%	43.54%
TSE:GPIN	49Neutral	CAD 7.30M	0.39	19.51%	―	―	-150.05%
TSE:ATLE	42Neutral	CAD 41.96M	-0.76	-2099.75%	―	-100.00%	94.43%
TSE:BNXT	41Neutral	CAD 35.38M	-3.52	117.02%	―	―	―

* Financial Sector Average

Performance Comparison

TSE:GPIN and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TSE:GPIN	Steep Hill Inc	0.18	-0.15	-45.29%
TSE:ATLE	Willow Biosciences	0.09	-0.07	-43.75%
TSE:LABS	Medipharm Labs (Otc)	0.07	-0.01	-13.33%
TSE:BNXT	Bionxt Solutions Inc	0.26	-0.57	-68.67%
TSE:INNO	Innocan Pharma Corporation	1.90	-16.10	-89.44%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Dec 30, 2025

Steep Hill Inc AI Stock Analysis